Zetia Cost in Wisconsin 2026: Ezetimibe Prices, Insurance, and Medicaid Coverage

What Does Zetia Actually Cost in Wisconsin in 2026?

The gap between brand and generic ezetimibe pricing in Wisconsin is large. Brand-name Zetia carries a list price near $380 per month, but generic ezetimibe at Wisconsin retail pharmacies runs approximately $15 per month on a cash-pay basis in 2026. Patients who still receive brand Zetia through insurance typically pay a specialty-tier copay that varies by plan design.

Ezetimibe became available as a generic in the United States in 2017. That single event collapsed out-of-pocket costs for most Wisconsin patients who pay cash. The FDA's generic drug program confirmed therapeutic equivalence of multiple generic manufacturers, meaning a pharmacist can legally substitute the generic without a new prescription in Wisconsin. [1]

Prices vary slightly by pharmacy chain. GoodRx and similar discount platforms routinely show ezetimibe 10 mg (30 tablets) at major Wisconsin chains, including Walgreens, CVS, and Pick 'n Save, for $10, $18. Independent pharmacies may price higher or lower depending on their wholesaler contracts. Calling the pharmacy directly before filling is the fastest way to confirm the exact price on a given day.

For clinical context, ezetimibe works by blocking the NPC1L1 transporter in the small intestine, which reduces dietary and biliary cholesterol absorption by roughly 50% and lowers LDL-C by 18 to 20% when used as monotherapy. [2] That mechanism is additive to statin therapy, which is why IMPROVE-IT (N=18,144) randomized patients on simvastatin to receive ezetimibe 10 mg or placebo and found an additional 24% LDL-C reduction and a 6.4% relative reduction in the composite cardiovascular endpoint at a median 6-year follow-up. [3]

The ACC/AHA 2018 Cholesterol Guideline lists ezetimibe as a first non-statin add-on for patients whose LDL-C remains above goal despite maximally tolerated statin therapy, supporting its place in treatment for most Wisconsin adults with elevated cardiovascular risk. [4]

Does Wisconsin Medicaid Cover Ezetimibe?

Wisconsin Medicaid covers ezetimibe, but a prior authorization (PA) request is required before the claim processes. Without PA approval, the pharmacy will return a rejected claim even if the generic is prescribed correctly.

Wisconsin's ForwardHealth program administers pharmacy benefits for Medicaid recipients. The PA criteria for ezetimibe generally require documentation that the patient has a qualifying lipid disorder, has tried or has a documented contraindication to a first-line statin, or needs combination therapy because statin monotherapy alone has not reached the LDL-C target. Prescribers submit PA requests through the ForwardHealth Portal, and approvals are typically granted or denied within one to three business days for standard reviews.

The American College of Cardiology has stated that "ezetimibe is a well-established, cost-effective therapy that should be accessible to high-risk patients without undue administrative burden." [4] For Wisconsin Medicaid patients who qualify, once PA is approved, their cost share is typically $0 to $3 per fill under most Wisconsin Medicaid benefit structures.

ForwardHealth covers generic ezetimibe; brand Zetia requires a separate medical necessity argument and is rarely approved when the generic is therapeutically equivalent. Patients denied PA have the right to appeal under federal Medicaid rules within 30 days of the denial notice. A prescriber letter citing IMPROVE-IT outcome data and the AHA/ACC guideline recommendation strengthens most appeals. [3][4]

Wisconsin Medicaid members should confirm their specific benefit tier by calling ForwardHealth member services at 800-362-3002 or logging into the ForwardHealth member portal.

Which Commercial Insurance Plans Cover Zetia in Wisconsin?

Most commercial plans in Wisconsin cover generic ezetimibe on Tier 1 or Tier 2, producing copays from $0 to $30 per month. Brand Zetia typically sits on Tier 3 or higher, where cost-sharing can reach $60, $150 per fill depending on the plan's formulary design.

Wisconsin's largest commercial insurers, including Anthem/BCBS of Wisconsin, Quartz, Common Ground Healthcare Cooperative, and Dean Health Plan, all list generic ezetimibe on their standard formularies for 2026. Patients should verify the exact tier by entering the drug name into their insurer's online formulary tool or by calling the member services number on their insurance card.

Employer-sponsored self-insured plans are governed by federal ERISA rules rather than Wisconsin state insurance mandates, meaning benefit design varies widely. A patient on a high-deductible health plan (HDHP) may pay the full discounted plan rate of $15, $35 per month until the deductible is met, after which the standard copay applies. [5]

Medicare Part D plans in Wisconsin placed generic ezetimibe on Tier 1 in most contracts reviewed for the 2026 plan year, typically producing a $0, $5 copay in the initial coverage phase. Beneficiaries can compare specific Part D plan formularies at the CMS Medicare Plan Finder tool or through the Wisconsin State Health Insurance Assistance Program (SHIP) at 800-242-1060.

Is Compounded Ezetimibe Legal in Wisconsin?

Compounded ezetimibe is legally available in Wisconsin through state-licensed 503A compounding pharmacies. The federal framework under Section 503A of the Federal Food, Drug, and Cosmetic Act permits patient-specific compounded preparations when a prescriber issues a valid prescription, the pharmacy is state-licensed, and the compound is not a copy of a commercially available product without clinical rationale. [6]

Ezetimibe is commercially available as a 10 mg tablet, so a 503A pharmacy in Wisconsin must document a patient-specific reason for compounding rather than dispensing the commercial generic. Common documented reasons include a patient allergy to a tablet excipient, the need for a liquid formulation for swallowing difficulties, or a custom combination with another agent not available commercially.

The FDA's guidance on 503A compounding is explicit that these pharmacies may not produce compounded drugs in anticipation of prescriptions in large quantities and may not compound drugs that are essentially copies of commercially available products without clinical justification. [6] Wisconsin pharmacies that compound ezetimibe must comply with both FDA guidance and Wisconsin Pharmacy Examining Board regulations.

In practice, some Wisconsin patients report paying little to nothing for compounded ezetimibe when it is included in a bundled telehealth or membership-based care program. These arrangements are legal when the prescribing and dispensing chain is fully licensed and the clinical rationale for compounding is documented in the patient record.

Can I Get a Zetia Prescription via Telehealth in Wisconsin?

Telehealth prescribing of ezetimibe is legal in Wisconsin. Ezetimibe is not a controlled substance, so the DEA's telemedicine prescribing rules for controlled substances do not apply. Wisconsin telemedicine law (Wis. Stat. ss. 448.975) permits a licensed prescriber to evaluate a patient via real-time audio-video and issue a valid prescription for a non-controlled drug, including ezetimibe, as long as an appropriate clinical evaluation occurs. [7]

Telehealth platforms operating in Wisconsin that prescribe cardiovascular and lipid-lowering medications typically require the patient to upload recent lipid panel results (ideally within 12 months), a list of current medications, and relevant cardiovascular history before the visit. A board-certified provider reviews the labs, determines appropriateness, and sends the prescription to the patient's preferred pharmacy or to a partnered compounding pharmacy if compounding is indicated.

The convenience factor is real. A Wisconsin patient in a rural county, say Ashland or Iron County, who would otherwise drive 90 minutes to a cardiologist can complete a telehealth visit in under 20 minutes and have ezetimibe dispensed locally the same day. The clinical standard of care for initial evaluation and monitoring is unchanged regardless of visit modality. Lipid panels should be rechecked 4 to 12 weeks after starting ezetimibe to confirm LDL-C response, consistent with ACC/AHA guideline recommendations. [4]

How Does the Merck Savings Card and Patient Assistance Work in Wisconsin?

Merck offers a savings card for brand Zetia that may reduce copays for commercially insured patients who do not use Medicaid or Medicare. In 2026, the card has been positioned to bring out-of-pocket cost to as low as $0 per month for eligible patients, subject to a monthly cap on the savings amount. Wisconsin residents must verify current eligibility and cap terms at the Merck patient assistance website because program terms change annually.

Patients without insurance or with Medicare Part D who do not qualify for the savings card may apply to the Merck Patient Assistance Program (Merck Helps). Income-based eligibility thresholds in 2026 are set near 400% of the federal poverty level, meaning a single Wisconsin adult earning under approximately $60,000 annually may qualify for free or deeply discounted brand Zetia.

For most Wisconsin patients, however, the generic at $15 per month is the simpler answer. The savings card is most relevant when a prescriber has documented a specific reason to use brand Zetia over the generic, or when the patient is already stabilized on brand Zetia and switching to generic has not been discussed.

GoodRx coupons at Wisconsin pharmacies routinely price generic ezetimibe between $10 and $18 for a 30-day supply. Blink Health and RxSaver show comparable prices. Stacking a coupon with a membership warehouse pharmacy (Costco, Sam's Club) sometimes produces prices under $10 per month for a 90-day supply divided across three months.

What Is the Clinical Evidence Supporting Ezetimibe Use?

Ezetimibe's cardiovascular benefit rests primarily on IMPROVE-IT, published in the New England Journal of Medicine in 2015. The trial enrolled 18,144 patients hospitalized for acute coronary syndrome and randomized them to simvastatin 40 mg plus ezetimibe 10 mg or simvastatin 40 mg plus placebo. At a median follow-up of 6 years, the combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the placebo arm. The primary composite endpoint of cardiovascular death, nonfatal MI, unstable angina, coronary revascularization, or nonfatal stroke occurred in 32.7% of the ezetimibe group versus 34.7% in the placebo group, an absolute risk reduction of 2.0 percentage points and a hazard ratio of 0.936 (P<0.001). [3]

That trial settled a long-standing debate about whether LDL-C lowering by non-statin mechanisms translates to clinical benefit. It does. The magnitude of cardiovascular risk reduction tracked closely with the degree of LDL-C lowering, consistent with the Cholesterol Treatment Trialists' meta-analysis of 26 statin trials. [8]

For patients with heterozygous familial hypercholesterolemia (HeFH), ezetimibe combined with a high-intensity statin is a standard of care option when LDL-C cannot be reduced below 100 mg/dL on a statin alone. The FDA approved ezetimibe (Zetia) for adjunct therapy to dietary and drug treatment in adults and pediatric patients 10 years and older with HeFH. [9]

Ezetimibe is generally well tolerated. The most reported adverse events in IMPROVE-IT were myalgia (5.3% ezetimibe vs. 5.5% placebo) and hepatic enzyme elevation above three times the upper limit of normal (0.5% vs. 0.5%), both statistically indistinguishable from placebo. [3] Liver function monitoring is not required routinely during ezetimibe therapy, though baseline hepatic enzyme measurement is reasonable in patients with known liver disease.

Drug interactions are limited. Cyclosporine increases ezetimibe exposure by roughly fivefold, so the combination requires careful monitoring. Bile acid sequestrants (cholestyramine, colesevelam) reduce ezetimibe absorption and should be dosed at least 2 hours before or 4 hours after ezetimibe. [9]

Comparing Ezetimibe to Other Non-Statin LDL-Lowering Options in Wisconsin

Wisconsin prescribers managing patients with statin intolerance or residual LDL-C elevation above goal have several non-statin options. Ezetimibe at $15 per month is the lowest-cost choice with strong cardiovascular outcome data. PCSK9 inhibitors (evolocumab, alirocumab) reduce LDL-C by 50 to 60% but list at $450, $600 per month and require step-therapy documentation through most Wisconsin commercial payers before approval. [10]

Bempedoic acid (Nexletol), approved by the FDA in 2020, reduces LDL-C by approximately 18% as monotherapy and does not require refrigeration, but lists near $300 per month. [11] The CLEAR Outcomes trial (N=13,970) demonstrated that bempedoic acid reduced major adverse cardiovascular events versus placebo in statin-intolerant patients at a mean follow-up of 3.4 years, providing outcome-level support comparable to IMPROVE-IT for ezetimibe. [12]

A practical Wisconsin prescribing decision framework for non-statin LDL-lowering:

1. Start with generic ezetimibe 10 mg once daily ($15/month, PA needed for Wisconsin Medicaid).
2. If LDL-C goal is not met after 6 to 8 weeks and the patient is high risk, add or substitute a PCSK9 inhibitor after completing insurer step-therapy requirements.
3. For statin-intolerant patients where ezetimibe alone is insufficient, consider bempedoic acid with CLEAR Outcomes data as support for PA requests.
4. For patients in bundled telehealth programs, compounded ezetimibe combinations may reduce total medication cost while preserving clinical efficacy, provided the 503A pharmacy documents clinical rationale.

Inclisiran (Leqvio), an siRNA-based PCSK9 inhibitor dosed twice yearly, received FDA approval in 2021 and is available in Wisconsin through select cardiology practices and specialty pharmacies, but list price exceeds $3,000 per injection, placing it far above ezetimibe on cost-effectiveness grounds for initial add-on therapy. [13]

How to Get the Cheapest Ezetimibe in Wisconsin: A Step-by-Step Path

Getting to $15 per month or below for ezetimibe in Wisconsin takes a few concrete steps. First, confirm with your prescriber that generic ezetimibe 10 mg is appropriate (it almost always is unless a specific excipient allergy exists). Second, use GoodRx, RxSaver, or Blink Health to identify the lowest price at pharmacies within driving distance or that offer mail-order. Third, ask the pharmacy whether a 90-day supply is available, since 90-day cash-pay fills at warehouse pharmacies sometimes reduce the per-month cost to $8, $12.

For Wisconsin Medicaid patients, the path is PA first. Your prescriber's office initiates the PA through the ForwardHealth Portal. Once approved, the copay is typically $0, $3. If the PA is denied, the prescriber can appeal using IMPROVE-IT outcome data [3] and the ACC/AHA guideline recommendation [4] as supporting documents.

For patients in telehealth programs, the prescribing visit itself may cost $0, $99, and some programs bundle the compounded medication with the visit fee. Confirm that the telehealth provider is licensed in Wisconsin and that the prescribing physician or advanced practice provider holds an active Wisconsin license before sharing any clinical information.

Lipid panels cost $10, $40 at walk-in labs in Wisconsin (Quest Diagnostics, LabCorp) without insurance. Getting a baseline and a 6-week follow-up panel adds roughly $20, $80 in total lab cost, which is still far below the cost of a single month of brand Zetia at list price.

The FDA's guidance on generic drug quality confirms that generic ezetimibe meets the same bioequivalence standards as brand Zetia, with an acceptable range of 80 to 125% AUC relative to the reference listed drug. [1] There is no clinical rationale for most patients to pay brand pricing when the generic is available and affordable.